67 results on '"Milionis H"'
Search Results
2. The possible role of TyG index and TRG/HDL, CRP/HDL, NEUTROPHILS/HDL lymphocytes/HDL ratios in disease severity and outcomes in COVID-19 hospitalized patients with arterial hypertension
3. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
4. Comparative effect of valsartan-amlodipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
5. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
6. Comparative effect of delapril-manidipine treatment versus valsartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
7. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in HOMA-IR, HOMA-B, HOMA-S and QUICKI indexes in prediabetic hypertensive patients
8. Comparative effect of delapril-manidipine treatment versus telmisartan-amlodipine treatment in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
9. Early vascular aging in acute ischemic stroke: A systematic review and meta-analysis.
10. Sodium-glucose cotransporter inhibitors protect against stroke in patients with type 2 diabetes and impaired renal function: A systematic review and meta-analysis
11. Residual cardiovascular risk in patients with dyslipidemia receiving multifactorial cardiovascular prevention therapy
12. PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 3-year regional lipid clinic experience
13. Effect of sodium-glucose contransporter-2 inhibitors on different subtypes of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
14. The effects of pioglitazone treatment in lipidemic profile and elastographic indices in non-diabetic patients with nash
15. PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting. A 2-year regional lipid clinic experience
16. Sodium-glucose transport protein 2 inhibitors and risk of incident stroke: A systematic review and meta-analysis
17. Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes: A Systematic Review And Meta-Analysis
18. Hyponatremia Is Associated With Increased The Mortality In Patients With Acute Stroke: A Systematic Review And Meta-Analysis
19. Characteristics and ten-year prognosis of patients treated with aspirin prior to a first-ever acute ischemic stroke. Data from the ‘Athens stroke outcome project’
20. Glucagon-like peptide 1 receptor agonists and protection against stroke: a systematic review and meta-analysis
21. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review.
22. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
23. Prospective Evaluation of Post-implantation Inflammatory Response After EVAR for AAA: Influence on Patients' 30 Day Outcome.
24. A review of drug-induced hyponatremia.
25. The effects of the addition of losartan or fenofibrate on the uric acid metabolism in patients receiving indapamide
26. Efficacy of combination of atorvastatin and micronized fenofibrate for the treatment of severe mixed lipid disorders
27. Liver function abnormalities in hyperlipidemic patients before and after hypolipidemic treatment
28. Abeta apolipoprotenaemia as a very rare cause of secondary amenorrhea.
29. W09.243 Metabolic syndrome in elderly patients suffering a first-ever acute ischemic stroke
30. MS448 DIFFERENTIAL EFFECT OF SARTANS WITH VARIOUS PPARγ ACTIVATING CAPACITY COMBINED WITH ROSUVASTATIN ON GLUCOSE METABOLISM INDICES
31. P430 THE BENEFICIAL EFFECT OF MEDITERRANEAN DIET ON METABOLIC SYNDROME: A META-ANALYSIS OF 49 STUDIES AND 175,529 INDIVIDUALS
32. Th-P16:381 Treating to target patients with primary hyperlipidemia: Comparison of the effects of atorvastatin and rosuvastatin (The atoros study)
33. W10-P-024 Beneficial effect of l-thyroxine onHDL-associated PAF-acetylhydrolase in patients with subclinical hypothyroidism
34. M.595 Lipoprotein(a) and acute-phase response in patients with vestibular neuronitis
35. M.596 Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
36. Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.
37. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
38. Impact of metabolic syndrome in surgical patients: should we bother?
39. Modifiable and non-modifiable cardiovascular risk factors on sensory disorder of smell and taste in COVID-19 population.
40. Association of cardiovascular risk factors and olfactory or taste dysfunction in COVID-19 population. Data from an academic center in Greece.
41. Statin treatment is associated with improved prognosis in patients with AF-related stroke.
42. Abstract: P322 ANTITHROMBOTIC AND ANTIATHEROGENIC EFFECT OF CLOPIDOGREL ON PATIENTS WITH ACUTE CORONARY SYNDROME
43. Th-P16:404 Effect of rosuvastatin on apolipoprotein CII and CIII serum levels in patients with primary dyslipidemia
44. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
45. 2.P.114 Lp(a) levels in patients with mild/moderate renal failure
46. 2.P.113 Lp(a) levels are different in patients with various types of primary hyperilipidemia
47. Liver PEComa. An extremely rare case report with complicated post-operative course.
48. EFFECTS OF ATORVASTATIN ON RED BLOOD CELL NA+/LI- COUNTETRANSPORT IN HYPERLIPIDEMIC PATIENTS WITH AND WITHOUT HYPERTENSION
49. 79 COMPARISON OF THE EFFECTS OF SIMVASTATIN VERSUS ROSUVASTATIN VERSUS SIMVASTATIN/EZETIMIBE ON PARAMETERS OF CARBOHYDRATE METABOLISM
50. Abstract: P383 COMBINING SARTANS OF DIFFERENT DEGREE OF PPARΓ ACTIVATING CAPACITY WITH ROSUVASTATIN IN PATIENTS WITH HYPERTENSION, IMPAIRED FASTING GLUCOSE AND MIXED DYSLIPIDEMIA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.